AstraZeneca: acquires Amolyt Pharma
(CercleFinance.com) - AstraZeneca announced on Monday that it had completed the acquisition of Amolyt Pharma, a French biotechnology company specialising in the treatment of rare endocrine diseases.
The biopharmaceutical group explains that this acquisition will enable Alexion, its subsidiary dedicated to rare diseases, to strengthen its expertise in cutting-edge endocrinology.
The transaction will lead to the acquisition of eneboparatide (AZP-3601), an experimental drug currently in phase III development for the treatment of hypoparathyroidism, a parathyroid hormone deficiency.
Under the terms of the agreement, AstraZeneca has paid $1.05bn in cash for the transaction, to which an additional $250m may be added, subject to the achievement of certain regulatory milestones.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The biopharmaceutical group explains that this acquisition will enable Alexion, its subsidiary dedicated to rare diseases, to strengthen its expertise in cutting-edge endocrinology.
The transaction will lead to the acquisition of eneboparatide (AZP-3601), an experimental drug currently in phase III development for the treatment of hypoparathyroidism, a parathyroid hormone deficiency.
Under the terms of the agreement, AstraZeneca has paid $1.05bn in cash for the transaction, to which an additional $250m may be added, subject to the achievement of certain regulatory milestones.
Copyright (c) 2024 CercleFinance.com. All rights reserved.